Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of KalVista Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P.

including KalVista Pharma's recently filed oral plasma kallikrein inhibitor sebetralstat. The lead investigator in the phase 2 trial, Danny Cohn of Amsterdam University Medical Center in the ...

After hours: January 24 at 4:01:53 p.m. EST ...

As of 10:53:03 AM EST. Market Open.

Healthcare Leader🥇* CEO 🏆* University Instructor 🎓* Podcast Host 🎤 * Medical Business Innovator 👩🏻🏫 * Justice Champion ⚖️* Patient Advocate🩺 ...